The role of visfatin in prostate cancer

Doctoral thesis English OPEN
Patel, Snehal T.
  • Subject: RC0254

The aim of this study was to investigate the role of the adipokine visfatin as a possible\ud molecular mediator between obesity and prostate cancer.\ud Visfatin, an adipokine that is elevated in obesity and has many proposed roles and has\ud been linked to a variety of cancers. No data pertaining to the role of visfatin in prostate\ud cancer existed and this was an area that this study looked to address. It is suggested\ud that obesity is a significant risk factor for prostate cancer; in particular, aggressive\ud disease and adipokines have been investigated as a link for this hypothesis.\ud This study presents novel data demonstrating the expression of visfatin in the LNCaP\ud and PC3 cell lines as well as in benign and cancerous prostate tissue at both mRNA\ud and protein level. Furthermore visfatin is shown to have functional roles in autoregulation\ud and promoting increased cell proliferation in PC3 cells and also showed\ud further effects with respect to cell migration across a wound. These data gave promise\ud to develop the study further and evaluate potential mechanisms of action including\ud common second messenger systems such as MAPK and also other oncologically\ud multifunctional molecules in the forms of MMP-2/-9. We then demonstrated that visfatin\ud up-regulated MAPK phosphorylation and MMP mRNA/protein expression and more\ud importantly MMP-2/-9 zymographic activity. This provided possible mechanisms by\ud which visfatin may mediate a role for obesity driven aggressive prostate cancer.\ud The study then looked to evaluate NMN (the byproduct of visfatin catalysed\ud biosynthetic activity), as well as the visfatin inhibitor FK866 which is being evaluated as\ud chemotherapeutic agent. Unsurprisingly NMN and FK866 had opposing actions on\ud proliferation and FK866 was naturally proapoptotic. NMN was able to rescue the effect\ud of FK866 on PC3 cell apoptosis. Prior studies have shown that NMN did not affect\ud oncogenes however NMN was found to significantly reduce BAX mRNA expression in\ud PC3 cells.\ud The findings are consistent with other studies linking visfatin with cancer states. These\ud novel data indicate roles for visfatin in prostate cancer and possible mechanisms linking\ud obesity and prostate cancer.
  • References (29)
    29 references, page 1 of 3

    [2] Bae SK, Kim SR, Kim JG, Kim JY, Koo TH, Jang HO, et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett 2006;580:4105-13.

    [3] Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005;54:2911-6.

    [4] Buschemeyer 3rd WC, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 2007;52:331-43.

    [5] Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.

    [6] Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, Lord JM. Serine/threonine protein kinases and apoptosis. Exp Cell Res 2002;34-41.

    [7] Deo DD, Rao AP, Bose SS, Ouhtit A, Baliga SB, Rao SA, et al. Differential effects of leptin on the invasive potential of androgen-dependent and -independent prostate carcinoma cells. J Biomed Biotechnol 2008;2008:163902.

    [8] Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev 2001;1:34-45.

    [9] Folgueira MA, Carraro DM, Brentani H, Patrao DF, Barbosa EM, Netto MM, et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005;11:7434-43.

    [10] Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 2007;29:88-97.

    [11] Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006;91:1578-81.

  • Metrics
    0
    views in OpenAIRE
    0
    views in local repository
    64
    downloads in local repository

    The information is available from the following content providers:

    From Number Of Views Number Of Downloads
    Warwick Research Archives Portal Repository - IRUS-UK 0 64
Share - Bookmark